CMS is unlikely to consider national coverage of radiation therapy for prostate cancer anytime soon because of insufficient evidence on the effectiveness of the treatment, according to Marcel Salive, director of medical and surgical services in CMS' Coverage and Analysis Group. "I do appreciate that this is an important public health problem and that it does have a lot of important clinical questions and questions of treatments and effectiveness that need to be answered," Salive said at a Medicare...